RENBIOLOGICS
DEAD

Serial Number

79395221

Owner

Biocytogen Pharmaceuticals (Beijing) Co., Ltd.

Filing Date

Dec 27, 2023

Add to watchlist:

No watchlists yet
View on USPTO

RENBIOLOGICS Trademark

Serial Number: 79395221

RENBIOLOGICS is a trademark filed by Biocytogen Pharmaceuticals (Beijing) Co., Ltd. on December 27, 2023. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific). The application is currently no longer active.

Owner Contact Info

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (12 trademarks)

No.12, Baoshen South Street,

Entity Type: 03

Trademark Details

Filing Date

December 27, 2023

Registration Date

Not Registered

Goods & Services

Medicines for human purposes; biological preparations for medical purposes; preparations of microorganisms for medical or veterinary use; biological tissue cultures for medical purposes; colostral antibodies for medical purposes; vaccines; living cells for medical purposes; biochemical medicines; pharmaceutical preparations; pharmaceutical substances; medical preparations for treating diseases and disorders related to the immune system; pharmaceutical preparations for the prevention and treatment of cancer; diagnostic preparations for medical purposes; dietetic substances adapted for medical use; medicines for veterinary purposes.

Protein [raw material]; radioactive elements for scientific purposes; preparations of trace elements for plants; biochemical preparations for scientific purposes; biological preparations, other than for medical or veterinary purposes; diagnostic preparations, other than for medical or veterinary purposes; biological tissue cultures other than for medical or veterinary purpose; bacteriological preparations other than for medical and veterinary use; preparations of microorganisms, other than for medical and veterinary use; proteins for the food industry.

Technological research; biochemical research and analysis; drug development; pharmaceutical product evaluation; clinical trials; research and development services in the field of antibodies; biological research; research in the field of gene editing technology; research in the field of cell engineering technology; culturing of cells for scientific research purposes; development of pharmaceutical preparations and pharmaceuticals; biomedical research.

Filing History

FINAL DECISION TRANSACTION PROCESSED BY IB
Mar 12, 2026 FINT
FINAL DISPOSITION NOTICE SENT TO IB
Feb 24, 2026 FICS
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Feb 24, 2026 FICR
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
Oct 24, 2025 OPNX
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Oct 8, 2025 OPNS
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
Oct 8, 2025 OPNR
ABANDONMENT NOTICE MAILED - FAILURE TO RESPOND
Feb 24, 2025 MAB2
ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE
Feb 24, 2025 ABN2
REFUSAL PROCESSED BY IB
Sep 1, 2024 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Aug 9, 2024 RFCS
REFUSAL PROCESSED BY MPU
Aug 9, 2024 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Jul 27, 2024 RFCR
NON-FINAL ACTION WRITTEN
Jul 26, 2024 CNRT
ASSIGNED TO EXAMINER
Jul 25, 2024 DOCK
APPLICATION FILING RECEIPT MAILED
May 15, 2024 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
May 15, 2024 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
May 9, 2024 REPR